Search

Your search keyword '"Junginger, H."' showing total 500 results
Start Over Author "Junginger, H."
500 results on '"Junginger, H."'

51. Biomass Resources: Agriculture

Author

Biobased Economy, Energy and Resources, Kluts, Ingeborg N., Brinkman, Marnix L. J., de Jong, Sierk A., Junginger, H. Martin, Biobased Economy, Energy and Resources, Kluts, Ingeborg N., Brinkman, Marnix L. J., de Jong, Sierk A., and Junginger, H. Martin

Published
2017

52. Modeling the impacts of wood pellet demand on forest dynamics in southeastern United States

Author

Biobased Economy, Energy System Analysis, Landdegradatie en aardobservatie, Energy and Resources, Landscape functioning, Geocomputation and Hydrology, Duden, Anna S., Verweij, Pita A., Junginger, H. Martin, Abt, Robert C., Henderson, Jesse D., Dale, Virginia H., Kline, Keith L., Karssenberg, Derek, Verstegen, Judith A., Faaij, André P.C., van der Hilst, Floor, Biobased Economy, Energy System Analysis, Landdegradatie en aardobservatie, Energy and Resources, Landscape functioning, Geocomputation and Hydrology, Duden, Anna S., Verweij, Pita A., Junginger, H. Martin, Abt, Robert C., Henderson, Jesse D., Dale, Virginia H., Kline, Keith L., Karssenberg, Derek, Verstegen, Judith A., Faaij, André P.C., and van der Hilst, Floor

Published
2017

55. New Drug Delivery Systems

Author

Vermeer, B. J., Place, V., Elias, P., Marks, R., Hadgraft, J., Mezei, M., Hannuksela, M., Junginger, H. E., Tiemessen, H. L. G. M., Boddé, H. E., van Driel, L. J. M., Schenkel, L., Orfanos, Constantin E., editor, Stadler, Rudolf, editor, and Gollnick, Harald, editor

Published
1988
Full Text
View/download PDF

58. Supply chain optimization of sugarcane first generation and eucalyptus second generation ethanol production in Brazil

Author

Biobased Economy, Energy System Analysis, Energy and Resources, Jonker, J. G G, Junginger, H. M., Verstegen, J. A., Lin, T., Rodríguez, L. F., Ting, K. C., Faaij, A. P C, van der Hilst, F., Biobased Economy, Energy System Analysis, Energy and Resources, Jonker, J. G G, Junginger, H. M., Verstegen, J. A., Lin, T., Rodríguez, L. F., Ting, K. C., Faaij, A. P C, and van der Hilst, F.

Published
2016

64. Abstracts of papers

Author

Roorda, W. E., de Vries, M. A., Kosho, C., Bouwstra, J. A., Junginger, H. E., Boddé, H. E., Kleinjan, C., de Bruyn, W. C., Daems, W. T., Kranenburg, T., van Driel, L. M. J., Roosjen, R., Gulot, H. F. L., de Vringer, T., Joosten, J. G. H., Jousma, H., Bouwstra, J., Gooris, G., Gooris, G. S., Tiemessen, H. L. G. M., Junsinger, H. E., Verhoeven, J., de Groot, J. J. H. U., Schaeffer, R. J., Peschier, L. J. C., Duchateau, G. S. M. J. E., Zuldema, J., Merkus, F. W. H. M., Pieters, F. A. J. M., Dekker, D., van Blools, L., Crommelin, D. J. A., Jiskoot, W., Offringa, J. C. A., Plekkenpol, R., Peeters, P. A. M., Claessens, A. C. M., Leufkens, P. W. J. T., Eling, W. M. C., Poelma, F. G. J., Tukker, J. J., Cromnelin, D. J. A., Storm, G., van Bloois, L., Brouwer, M., Talsma, H., Blankenstein, M. A., Nortier, J. W. R., Bakri, A., Wilting, J., Janssen, L. H. H., Crommelin, P. J. A., Mathieu, A. M., van Ooteghem, M., Ludwig, A., Breimer, D. D., de Boer, A. G., Kleinbloesem, C. H., van Brummelen, P., Danhof, M., Urquhart, J., Bolhuis, G. K., van Kamp, H. V., Proost, J. H., Lerk, C. F., de Boer, A. H., Vromans, H., de Haan, P., Schoonen, A. J. M., de Vries-Nijboer, G. W., Bosch, E. H., Kussendrager, K. D., van Saene, H. K. F., Mahieu, H. F., van Saene, J. J. M., Baaijens, L., Middelbeek, E., van Rooy, R., Vissers, M. J. C., Baaljens, L., Sam, A. P., Boer, Y., Janknegt, D., Cox, H. L. M., de Meijer, P. J. J., Kloeg, P. H. A. M., Mensink, C. K., van de Vaart, F. J., Roggen, W., Boom, F. A., Paalman, A. C. A., Vos, Th., de Gier, J. J., Takken-Hillebrecht, A., van Lakwijk-Najoan, J. A. L., Leufkens, H. G. M., and Paes, A. H. P.

Published
1986
Full Text
View/download PDF

77. Biowaiver monographs for immediate release solid oral dosage forms: prednisolone

Author

Vogt, M, Derendorf, H, Krämer, J, Junginger, H E, Midha, K K, Shah, V P, Stavchansky, S, Dressman, J B, and Barends, D M

Abstract

Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing prednisolone are reviewed. Data on its solubility, oral absorption, and permeability are not totally conclusive, but strongly suggest a BCS Class 1 classification. Prednisolone's therapeutic indications and therapeutic index, pharmacokinetics, and the possibility of excipient interactions were also taken into consideration. Available evidence indicates that a biowaiver for IR solid oral dosage forms formulated with the excipients tabulated in this article would be unlikely to expose patients to undue risks.

Published
2007

78. Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol)

Author

Kalantzi, L, Reppas, C, Dressman, J B, Amidon, G L, Junginger, H E, Midha, K K, Shah, V P, Stavchansky, S A, and Barends, Dirk M

Subjects
digestive, oral, and skin physiology
Abstract

Literature data are reviewed on the properties of acetaminophen (paracetamol) related to the biopharmaceutics classification system (BCS). According to the current BCS criteria, acetaminophen is BCS Class III compound. Differences in composition seldom, if ever, have an effect on the extent of absorption. However, some studies show differences in rate of absorption between brands and formulations. In particular, sodium bicarbonate, present in some drug products, was reported to give an increase in the rate of absorption, probably caused by an effect on gastric emptying. In view of Marketing Authorizations (MAs) given in a number of countries to acetaminophen drug products with rapid onset of action, it is concluded that differences in rate of absorption were considered therapeutically not relevant by the Health Authorities. Moreover, in view of its therapeutic use, its wide therapeutic index and its uncomplicated pharmacokinetic properties, in vitro dissolution data collected according to the relevant Guidances can be safely used for declaring bioequivalence (BE) of two acetaminophen formulations. Therefore, accepting a biowaiver for immediate release (IR) acetaminophen solid oral drug products is considered scientifically justified, if the test product contains only those excipients reported in this paper in their usual amounts and the test product is rapidly dissolving, as well as the test product fulfils the criterion of similarity of dissolution profiles to the reference product.

Published
2007

79. Biowaiver monographs for immediate release solid oral dosage forms: cimetidine

Author

Jantratid, E, Prakongpan, S, Dressman, J B, Amidon, G L, Junginger, H E, Midha, K K, and Barends, D M

Abstract

Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing cimetidine are reviewed. According to the current Biopharmaceutics Classification System (BCS), cimetidine would be assigned to Class III. Cimetidine's therapeutic use and therapeutic index, its pharmacokinetic properties, data related to the possibility of excipient interactions, and reported BE/bioavailability (BA) problems were also taken into consideration. On the basis of the overall evidence, a biowaiver can be recommended for cimetidine IR products, provided that the test product contains only those excipients reported in this paper in their usual amounts, and that the test and the comparator drug products both are "rapidly dissolving" as per BCS.

Published
2007

80. Abstracts of papers biopharmaceutical meeting

Author

Hofland, H. E. J., Bouwstra, J. A., Talsma, H., Spies, F., Junginger, H. E., Vromans, H., Lerk, C. F., van Hoogdalem, E. J., Wackwitz, A. T. E., de Boer, A. G., Cohen, A. F., Breimer, D. D., van der Graaff, M., van den Oetelaar, P. J. M., Brinks, G. J., Peschier, L. J. C., Boddé, H. E., Brussee, H., Tukker, J J, van Doorne, H., de Smidt, P. D., van Dijk, M. C. M., and van Berkel, Th. J. C.

Published
1988
Full Text
View/download PDF

81. Abstracts of papers biopharmaceutical meeting

Author

Storm, G., Nässander, U., Steerenberg, P. A., Roerdink, F., Crommelin, D. J. A., Schacht, E., Vermeersch, J., Duncan, R., Boddé, H. E., Junginger, H. E., de Groot, P., de Bruyn, U. C., Daems, W. T., de Meere, A. L. J., Grünbauer, H. J. M., van Rooy, H. H., van Bos, M., van Saene, J. J. M., van Saene, H. K. F., Lerk, C. F., de Greet, H., de Smidt, J., Crommelin, D. J. A., Tiemessen, H. L. G. M., Jousma, H., van der Schoot, J. B., and Philips, W. E.

Published
1985
Full Text
View/download PDF

82. Abstracts of papers biopharmaceutical meeting

Author

Ludwig, A., Van Ooteghem, M., Tiemessen, H. L. G. M., Boddé, H. E., van Mourik, C., Trouerbach, M., Jousma, H., Junginger, H. E., de Smidt, J. H., Grit, M., Crommelin, D. J. A., Goedemoed, J. H., de Groot, K., Bos, C. E., Bolhuis, G. K., van Doorne, H., Lerk, C. F., Roorda, W. E., Bouwstra, J. A., de Vries, M. A., de Bleyser, J., Leyte, J. C., Storm, G, van Bloois, L, Brouwer, M, Crommelin, D J A, Pieters, F. A. J. M., Zuidema, J., Bootsma, H. P. R., van Hoogdalem, E. J., Hardens, H. A., de Boer, A. G., and Breimer, D. D.

Published
1987
Full Text
View/download PDF

83. Abstracts of papers biopharmaceutical meeting

Author

Wolterink, G., van Ree, J. M., van Hoogdalem, E. J., Stijnen, A. M., de Boer, A. G., Breimer, D. D., Nässander, U. K., Storm, G., Steerenberg, P. A., de Jong, H. H., Crommelin, D. J. A., Sam, A. P., Zwinkels, J., Timmer, C. J., Beach, C. A., de Nijs, H., Peeters, P. A. M., Eling, W. M. C., de Leede, L. G. J., Govers, C. P. M., Timmer, C. J., Geelen, J. A. A., de Vringer, T., Junginger, H. E., Joosten, J. G. H., Boddé, H. E., van der Graaff, M., Brinks, G., Kruyt, G., de Ruiter, M., Van Ooteghem, M., Ludwig, A., de Smidt, J. H., Kuypers, H. H. A., and Offringa, J. C. A.

Published
1986
Full Text
View/download PDF

86. Monitoring Sustainability Certification of Bioenergy - Short Summary

Author

Pelkmans, L., Goovaerts, L., Stupak, I., Smith, C. T., Goh, C.S., Junginger, H. M., Chum, H., Goss Eng, A., Cowie, A., Englund, Oskar, Joudrey, J., Dahlman, L., Pelkmans, L., Goovaerts, L., Stupak, I., Smith, C. T., Goh, C.S., Junginger, H. M., Chum, H., Goss Eng, A., Cowie, A., Englund, Oskar, Joudrey, J., and Dahlman, L.

Published
2013

87. Biowaiver monographs for immediate release solid oral dosage forms: Pyrazinamide A project of the International Pharmaceutical Federation FIP, Groupe BCS, www.fip.org/bcs . This article reflects the scientific opinion of the authors and not the policies of regulating agencies.

Author

College of Pharmacy, University of Michigan, Ann Arbor, Michigan, Institute of Pharmaceutical Technology, J.W. Goethe University, Frankfurt, Germany, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand, WHO???World Health Organization, Geneva, Switzerland, University of Saskatchewan, Saskatoon, Saskatchewan, Canada, International Pharmaceutical Federation FIP, The Hague, The Netherlands, Pharmaceutical Division, College of Pharmacy, University of Texas at Austin, Austin, Texas, RIVM???National Institute for Public Health and the Environment, Bilthoven, The Netherlands ; RIVM???National Institute for Public Health and the Environment, Bilthoven, The Netherlands. Telephone: 31-30-2744209; Fax: 31-30-2744462., Becker, C., Dressman, J. B., Amidon, G. L., Junginger, H. E., Kopp, S., Midha, K. K., Shah, V. P., Stavchansky, S., Barends, D. M., College of Pharmacy, University of Michigan, Ann Arbor, Michigan, Institute of Pharmaceutical Technology, J.W. Goethe University, Frankfurt, Germany, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand, WHO???World Health Organization, Geneva, Switzerland, University of Saskatchewan, Saskatoon, Saskatchewan, Canada, International Pharmaceutical Federation FIP, The Hague, The Netherlands, Pharmaceutical Division, College of Pharmacy, University of Texas at Austin, Austin, Texas, RIVM???National Institute for Public Health and the Environment, Bilthoven, The Netherlands ; RIVM???National Institute for Public Health and the Environment, Bilthoven, The Netherlands. Telephone: 31-30-2744209; Fax: 31-30-2744462., Becker, C., Dressman, J. B., Amidon, G. L., Junginger, H. E., Kopp, S., Midha, K. K., Shah, V. P., Stavchansky, S., and Barends, D. M.

Abstract

Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing pyrazinamide as the only active pharmaceutical ingredient (API) are reviewed. Pyrazinamide is BCS Class III, with linear absorption over a wide dosing range. The risk of bio in equivalence is estimated to be low. Depending on the definition used, pyrazinamide can be classified as a narrow therapeutic index (NTI) drug, which is usually a caveat to biowaiving but may be deemed acceptable if the Summary of Product Characteristics (SmPCs) of the test product stipulates the need for regular monitoring of liver function. It is concluded that a biowaiver can be recommended for IR solid oral dosage only when the test product (a) contains only excipients present in pyrazinamide IR solid oral drug products approved in ICH or associated countries, (b) these excipients are present in amounts normally used in IR solid oral dosage forms, (c) the test product is very rapidly dissolving , (d) the SmPC of the test product indicates the need for monitoring of the patient's liver function. ?? 2008 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 97:3709???3720, 2008

Published
2008

88. Biowaiver monographs for immediate release solid oral dosage forms: ethambutol dihydrochloride This paper reflects the scientific opinion of the authors and not the policies of regulating agencies. A project of the International Pharmaceutical Federation FIP, Groupe BCS, http://www.fip.org/bcs .

Author

College of Pharmacy, University of Michigan, Ann Arbor, Michigan, Institute of Pharmaceutical Technology, J.W. Goethe University, Frankfurt am Main, Germany, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand, World Health Organization, Geneva, Switzerland, University of Saskatchewan, Saskatoon, Saskatchewan, Canada, International Pharmaceutical Federation FIP, Den Haag, The Netherlands, Division of Pharmaceutics, College of Pharmacy, University of Texas at Austin, Austin, Texas, RIVM???National Institute for Public Health and the Environment, Bilthoven, The Netherlands ; RIVM???National Institute for Public Health and the Environment, Bilthoven, The Netherlands. Telephone: +31-30-2744209; Fax: +31-30-2744462, Becker, C., Dressman, J. B., Amidon, G. L., Junginger, H. E., Kopp, S., Midha, K. K., Shah, V. P., Stavchansky, S., Barends, D. M., College of Pharmacy, University of Michigan, Ann Arbor, Michigan, Institute of Pharmaceutical Technology, J.W. Goethe University, Frankfurt am Main, Germany, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand, World Health Organization, Geneva, Switzerland, University of Saskatchewan, Saskatoon, Saskatchewan, Canada, International Pharmaceutical Federation FIP, Den Haag, The Netherlands, Division of Pharmaceutics, College of Pharmacy, University of Texas at Austin, Austin, Texas, RIVM???National Institute for Public Health and the Environment, Bilthoven, The Netherlands ; RIVM???National Institute for Public Health and the Environment, Bilthoven, The Netherlands. Telephone: +31-30-2744209; Fax: +31-30-2744462, Becker, C., Dressman, J. B., Amidon, G. L., Junginger, H. E., Kopp, S., Midha, K. K., Shah, V. P., Stavchansky, S., and Barends, D. M.

Abstract

Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing ethambutol dihydrochloride as the only active pharmaceutical ingredient (API) are reviewed. Ethambutol dihydrochloride is a Biopharmaceutics Classification System (BCS) Class III drug with permeability properties approaching the border between BCS Class I and III. BE problems of ethambutol formulations containing different excipients and different dosages forms have not been reported and hence the risk of bio in equivalence caused by excipients is low. Ethambutol has a narrow therapeutic index related to ocular toxicity. However, as long as the prescribers' information of the test product stipulates the need for regular monitoring of ocular toxicity, the additional patient risk is deemed acceptable. It is concluded that a biowaiver can be recommended for IR solid oral dosage forms provided that the test product (a) contains only excipients present in ethambutol IR solid oral drug products approved in ICH or associated countries, for instance as presented in this paper, (b) complies with the criteria for ???very rapidly dissolving??? and (c) has a prescribers' information indicating the need for testing the patient's vision prior to initiating ethambutol therapy and regularly during therapy. ?? 2007 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 97:1350???1360, 2008

Published
2008

97. Abstracts of papers

Author

Crommelin', D. J. A., van Dalen, F., Kersten, G. F. A., van der Put, A. M. H., Teerlink, T., Beuvery, E. C., de Boer, A. H., Vromans, H., Lerk, C. F., de Haan, P., Saettone, M. F., Giannaccini, B., Naber, L., Frijlink, H. W., Schoonen, A. J. M., Moolenaar, F., Meijer, D. K. F., Verhoeven, J., de Vries, M. E., and Junginger, H. E.

Published
1987
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results